Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

August 12, 2016

Primary Completion Date

April 18, 2019

Study Completion Date

April 18, 2019

Conditions
Heart FailureHealthy Volunteer
Interventions
DRUG

AMG 986 IV

AMG 986 solution for infusion

DRUG

AMG 986 PO

AMG 986 tablets for oral (PO) administration

DRUG

Placebo PO

Matching placebo tablets for oral administration

DRUG

Placebo IV

Matching placebo solution for infusion

Trial Locations (25)

3083

Research Site, Bundoora

3806

Research Site, Berwick

4066

Research Site, Auchenflower

4670

Research Site, Bundaberg

5068

Research Site, Leabrook

8011

Research Site, Christchurch

13353

Research Site, Berlin

21201

Research Site, Baltimore

27705

Research Site, Durham

31059

Research Site, Toulouse

32216

Research Site, Jacksonville

35033

Research Site, Rennes

44093

Research Site, Nantes

55415

Research Site, Minneapolis

61231

Research Site, Bad Neuheim

70006

Research Site, Metairie

75015

Research Site, Paris

89148

Research Site, Las Vegas

92780

Research Site, Tustin

92801

Research Site, Anaheim

169609

Research Site, Singapore

J1G 2E8

Research Site, Sherbrooke

9713 GZ

Research Site, Groningen

05-410

Research Site, Józefów

51-162

Research Site, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03276728 - Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients | Biotech Hunter | Biotech Hunter